Afficher la notice abrégée

25-hydroxyvitamin D sufficiency is associated with lower de novo anti-HLA donor specific antibody and better kidney transplant outcomes.

dc.rights.licenseopenen_US
dc.contributor.authorBAKIS, Hugo
hal.structure.identifierImmunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
dc.contributor.authorBOUTHEMY, Charlene
hal.structure.identifierNutrition et Neurobiologie intégrée [NutriNeuro]
dc.contributor.authorCORCUFF, Jean-Benoît
dc.contributor.authorLAURO, Cindy
dc.contributor.authorGUIDICELLI, Gwendaline
dc.contributor.authorCARGOU, Marine
dc.contributor.authorGUIBET, Claire
dc.contributor.authorTATON, Benjamin
hal.structure.identifierImmunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
dc.contributor.authorMERVILLE, Pierre
hal.structure.identifierImmunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
dc.contributor.authorCOUZI, Lionel
dc.contributor.authorMOREAU, Karine
hal.structure.identifierImmunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
dc.contributor.authorVISENTIN, Jonathan
dc.date.accessioned2023-10-05T12:32:44Z
dc.date.available2023-10-05T12:32:44Z
dc.date.issued2023-08-21
dc.identifier.issn2059-2310en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/184337
dc.description.abstractEnT-cell mediated rejection (TCMR), de novo anti-HLA donor-specific antibodies (dnDSAs) and ensuing antibody-mediated rejection (ABMR) reduce kidney transplantation (KT) survival. The immunomodulatory effects of 25-hydroxyvitamin D [25(OH)D] could be beneficial for KT outcomes. We aimed to evaluating the association between 25(OH)D levels, the development of dnDSAs, clinical TCMR and ABMR, and graft survival. This single center retrospective study included 253 KT recipients (KTRs) transplanted without preformed DSA between 2010 and 2013. We measured 25(OH)D in successive serum samples: at KT (M0) and M12 for the entire cohort, and additionally at M24 and/or M36 when sera were available. We assessed graft outcomes up to 5 years post-KT. The proportion of KTRs having sufficient 25(OH)D at KT (M0) was high (81.4%) and then dropped at M12 (71.1%). KTRs with sufficient 25(OH)D at M0 experienced less clinical TCMR (HR, 0.41; 95% CI, 0.19-0.88 in multivariate analysis). A sufficient 25(OH)D at M12 was independently associated with a longer dnDSA-free survival (HR, 0.34; 95% CI, 0.17-0.69). There was no association between 25(OH)D and clinical AMBR. Studying the KTRs with 25(OH)D measurements at M12, M24 and M36 (n = 203), we showed that 25(OH)D sufficiency over the 3 first-years post-KT was associated with a longer graft survival in multivariate analyses (HR, 0.39; 95% CI, 0.22-0.70). To our knowledge, this study is the first showing an association between 25(OH)D sufficiency post-KT and dnDSA occurrence in KTRs. Moreover, we reinforce previously published data showing an association between 25(OH)D, TCMR and graft survival in KT.
dc.language.isoENen_US
dc.subject.enDonor-specific antibodies
dc.subject.enGraft loss
dc.subject.enImmunomodulation
dc.subject.enKidney transplantation
dc.subject.enVitamin D
dc.title.en25-hydroxyvitamin D sufficiency is associated with lower de novo anti-HLA donor specific antibody and better kidney transplant outcomes.
dc.title.alternativeHLAen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1111/tan.15187en_US
dc.identifier.pubmed37604171en_US
bordeaux.journalHLA: Immune Response Geneticsen_US
bordeaux.hal.laboratoriesNutriNeuro (Laboratoire de Nutrition et Neurobiologie Intégrée) - UMR 1286en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionBordeaux INPen_US
bordeaux.institutionINRAEen_US
bordeaux.institutionCNRS
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
workflow.import.sourcepubmed
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=HLA:%20Immune%20Response%20Genetics&rft.date=2023-08-21&rft.eissn=2059-2310&rft.issn=2059-2310&rft.au=BAKIS,%20Hugo&BOUTHEMY,%20Charlene&CORCUFF,%20Jean-Beno%C3%AEt&LAURO,%20Cindy&GUIDICELLI,%20Gwendaline&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée